NYSE - Delayed Quote USD
Emergent BioSolutions Inc. (EBS)
At close: October 21 at 4:00 PM EDT
Pre-Market: 4:03 AM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,074,400.00
1,023,000.00
1,076,100.00
1,639,400.00
1,462,200.00
Cost of Revenue
802,600.00
705,400.00
693,100.00
748,100.00
537,000.00
Gross Profit
271,800.00
317,600.00
383,000.00
891,300.00
925,200.00
Operating Expense
476,000.00
519,100.00
546,300.00
508,200.00
486,700.00
Operating Income
-204,200.00
-201,500.00
-163,300.00
383,100.00
438,500.00
Net Non Operating Interest Income Expense
-89,300.00
-87,900.00
-37,300.00
-34,500.00
-31,300.00
Other Income Expense
-284,600.00
-441,800.00
-18,400.00
-45,400.00
4,700.00
Pretax Income
-578,100.00
-731,200.00
-219,000.00
303,200.00
411,900.00
Tax Provision
8,900.00
29,300.00
-7,400.00
83,700.00
106,100.00
Net Income Common Stockholders
-587,000.00
-760,500.00
-211,600.00
219,500.00
305,800.00
Diluted NI Available to Com Stockholders
-587,000.00
-760,500.00
-211,600.00
219,500.00
305,800.00
Basic EPS
-11.22
-14.85
-4.47
4.32
5.79
Diluted EPS
-11.22
-14.85
-4.47
4.27
5.67
Basic Average Shares
52,150.00
51,200.00
50,100.00
53,500.00
52,700.00
Diluted Average Shares
52,150.00
51,200.00
50,100.00
54,100.00
53,800.00
Total Operating Income as Reported
-449,600.00
-726,400.00
-170,000.00
341,400.00
438,500.00
Total Expenses
1,278,600.00
1,224,500.00
1,239,400.00
1,256,300.00
1,023,700.00
Net Income from Continuing & Discontinued Operation
-587,000.00
-760,500.00
-211,600.00
219,500.00
305,800.00
Normalized Income
-360,981.00
-404,447.00
-205,101.00
249,524.00
305,800.00
Interest Expense
89,300.00
87,900.00
37,300.00
34,500.00
31,300.00
Net Interest Income
-89,300.00
-87,900.00
-37,300.00
-34,500.00
-31,300.00
EBIT
-488,800.00
-643,300.00
-181,700.00
337,700.00
443,200.00
EBITDA
-374,800.00
-518,200.00
-38,400.00
461,500.00
557,700.00
Reconciled Cost of Revenue
753,600.00
645,900.00
609,700.00
682,800.00
482,300.00
Reconciled Depreciation
114,000.00
125,100.00
143,300.00
123,800.00
114,500.00
Net Income from Continuing Operation Net Minority Interest
-587,000.00
-760,500.00
-211,600.00
219,500.00
305,800.00
Total Unusual Items Excluding Goodwill
-286,100.00
-450,700.00
-6,700.00
-41,700.00
--
Total Unusual Items
-286,100.00
-450,700.00
-6,700.00
-41,700.00
--
Normalized EBITDA
-88,700.00
-67,500.00
-31,700.00
503,200.00
557,700.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-60,081.00
-94,647.00
-201.00
-11,676.00
--
12/31/2020 - 11/15/2006
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SIGA SIGA Technologies, Inc.
6.88
-0.58%
AKAN Akanda Corp.
1.0700
-2.73%
ESPR Esperion Therapeutics, Inc.
2.0600
+0.98%
DVAX Dynavax Technologies Corporation
10.98
+0.27%
ELTP Elite Pharmaceuticals, Inc.
0.7100
+0.71%
BHC Bausch Health Companies Inc.
8.17
+0.12%
CRDL Cardiol Therapeutics Inc.
1.9100
-0.52%
AQST Aquestive Therapeutics, Inc.
4.9500
-1.59%
UPC Universe Pharmaceuticals INC
0.4043
-3.05%
SXTC China SXT Pharmaceuticals, Inc.
0.6794
+7.82%